Indian Journal of Urology
REVIEW ARTICLE
Year
: 2021  |  Volume : 37  |  Issue : 3  |  Page : 226--233

Perioperative therapy in muscle invasive bladder cancer


Ambarish Chatterjee, Ganesh Bakshi, Mahendra Pal, Akhil Kapoor, Amit Joshi, Gagan Prakash 
 Department of Uro-Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India

Correspondence Address:
Gagan Prakash
Department of Uro-Oncology, Tata Memorial Centre, Mumbai, Maharashtra
India

Radical cystectomy with bilateral pelvic lymph node dissection is the standard of care for muscle invasive bladder cancer (MIBC). The role of neoadjuvant and adjuvant therapy has evolved over the last 3–4 decades, and neoadjuvant chemotherapy (NACT) has now become the standard recommended treatment. However, there are many nuances to this and the utilization of chemotherapy has not been universal. The optimum chemotherapy regimen is still debated. Adjuvant radiation has a role in high-risk patients although not established and immunotherapy has shown promising results. We reviewed the evidence on NACT and adjuvant chemotherapy (ACT) regimens, NACT versus ACT, and the role of adjuvant radiotherapy and immunotherapy in MIBC.


How to cite this article:
Chatterjee A, Bakshi G, Pal M, Kapoor A, Joshi A, Prakash G. Perioperative therapy in muscle invasive bladder cancer.Indian J Urol 2021;37:226-233


How to cite this URL:
Chatterjee A, Bakshi G, Pal M, Kapoor A, Joshi A, Prakash G. Perioperative therapy in muscle invasive bladder cancer. Indian J Urol [serial online] 2021 [cited 2021 Sep 17 ];37:226-233
Available from: https://www.indianjurol.com/article.asp?issn=0970-1591;year=2021;volume=37;issue=3;spage=226;epage=233;aulast=Chatterjee;type=0